Study: NCT04390399

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N-803
Description: Recombinant human super agonist interleukin-15 (IL-15) complex

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N-803
Description: Recombinant human super agonist interleukin-15 (IL-15) complex

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N-803
Description: Recombinant human super agonist interleukin-15 (IL-15) complex

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N-803
Description: Recombinant human super agonist interleukin-15 (IL-15) complex

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldoxorubicin HCl
Description: Aldoxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldoxorubicin HCl
Description: Aldoxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldoxorubicin HCl
Description: Aldoxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldoxorubicin HCl
Description: Aldoxorubicin hydrochloride

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-L1 t-haNK
Description: PD-L1 t-haNK suspension for infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-L1 t-haNK
Description: PD-L1 t-haNK suspension for infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-L1 t-haNK
Description: PD-L1 t-haNK suspension for infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 2', 2'-difluoro 2'deoxycytidine, dFdC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 2', 2'-difluoro 2'deoxycytidine, dFdC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 2', 2'-difluoro 2'deoxycytidine, dFdC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 2', 2'-difluoro 2'deoxycytidine, dFdC